Anti-human Cripto-1 antibody

A technology of antibodies and monoclonal antibodies, applied in the direction of antibodies, anti-animal/human immunoglobulins, anti-tumor drugs, etc., can solve problems that are unlikely to cure cancer

Pending Publication Date: 2022-07-08
GSP ENTERPRISE INC +2
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clearly, existing cancer drugs, including molecularly targeted drugs, are unlikely to cure cancer because these drugs only act on specific cancer cells within the cell population present in cancerous tissues and show heterogeneity for the rest of cancer cells or cancer stem cells do not work

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human Cripto-1 antibody
  • Anti-human Cripto-1 antibody
  • Anti-human Cripto-1 antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0180] Example 1: Screening of anti-human Cripto-1 antibodies

[0181] Phage-displayed human antibody libraries were screened for antibodies that specifically recognized the extracellular domain of human Cripto-1. The extracellular domain of human Cripto-1 contains the amino acid sequence represented by SEQ ID NO: 11, and has a His-tag sequence having the amino acid sequence represented by SEQ ID NO: 12 at its N-terminus. The extracellular domain of human Cripto-1 was prepared in its soluble form according to the method described in Alam. et.al., Int J Mol Sci. 2018, 26; 19(11). Antibody libraries used as screening targets are described in Sakai, K. et al., Biochemistry 46(1):253-62, and the subclass of antibodies is IgG.

[0182] As a result, the #35 cloned phage strain was obtained as an antibody that specifically recognized the extracellular domain of purified human Cripto-1. The nucleotide sequence encoding the antibody was analyzed based on the clone, and based on the...

Embodiment 2

[0186] Example 2: Evaluation of antigen recognition ability by ELISA

[0187] The culture supernatant of clone #35 antibody was collected and diluted 25-fold with phosphate buffer, followed by further serial dilutions every 2-fold. The diluted culture supernatant was added to a 96-well plate, and IgG molecules (anti-human Cripto-1 antibody of human origin) adsorbed on each well were detected with HRP-labeled anti-human IgG goat antibody (manufactured by Abcam) . figure 2 Results are shown.

[0188] like figure 1 As shown in , the staining by HRP decreased with the degree of dilution of the culture supernatant containing the #35 clone antibody. This indicates that the #35 clone antibody is specifically adsorbed to its antigen, human Cripto-1.

Embodiment 3

[0189] Example 3: Evaluation of specificity against (human) cancer tissue using tissue arrays

[0190] Immunostaining was performed on human cancer tissue array (BCN801, US Biomax Inc.). Clone #35 was used as the primary antibody. ALEXA568-labeled anti-human IgG goat antibody (Invitrogen) was used as secondary antibody to detect each cancer tissue (pancreatic cancer tissue, thyroid cancer tissue, prostate cancer tissue, gastric cancer tissue, cervical cancer tissue, colorectal cancer tissue and breast cancer tissue tissue) in human Cripto-1. These cancer tissues contain cancer stem cells as well as cancer cells, and it is believed that Cripto-1 is bound to the surface of the cell membrane of cancer stem cells through a GPI-anchor. In negative control experiments, signal background was determined by using only the secondary antibody. Figures 3 to 5 Results are shown.

[0191] like Figures 3 to 5 Shown in , staining images of the #35 clone antibody were identified in al...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention addresses the problem of developing a technique for inhibiting cancer stem cells. Therefore, the solution provides an anti-human Cripto-1 antibody of human origin having a specific amino acid sequence.

Description

technical field [0001] The present invention relates to, for example, monoclonal antibodies that specifically recognize the structure of the extracellular domain of human Cripto-1. The present invention also relates to eg a food or beverage composition or a pharmaceutical composition comprising a monoclonal antibody that specifically recognizes the structure of the extracellular domain of human Cripto-1. Background technique [0002] Recent cancer research has revealed that cancer tissue is not a homogeneous collection of cells, but a collection of cells with a heterogeneous nature. In addition, it is known that cancer tissues contain cancer stem cells, and when cancer cells are differentiated from cancer stem cells, cancer stem cells themselves proliferate. [0003] Permanent cure of cancer is actually generally considered difficult, as evidenced by the fact that the therapeutic effects of existing cancer drugs are even expressed in terms of "five-year survival rate". App...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/13
CPCA23L33/18A61P35/00C07K16/2863C07K16/22C07K2317/21C07K2317/73C12N5/0693C07K16/30A23V2002/00A61K2039/505A23V2200/308A23L33/175C07K2317/565C07K2317/732C07K2317/734
Inventor 妹尾昌治高柳淳李世京
Owner GSP ENTERPRISE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap